Daniel Rabinowitz, Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold a significant portion of its stake in the company. The sale comes as Natera’s shares are trading near a 52-week high of $177, after posting an impressive 177.73% return over the past year. With a market capitalization of $23.14 billion, the company maintains a GOOD financial performance according to InvestingPro analysis. According to a filing with the Securities and Exchange Commission, Rabinowitz sold 6,223 shares of common stock on January 8, 2025. The shares were sold at a weighted average price of $175.3015, generating a total of approximately $1,090,901.
This transaction was made as part of a prearranged trading plan pursuant to Rule 10b5-1, which Rabinowitz adopted on June 14, 2024. Following the sale, Rabinowitz retains direct ownership of 199,804 shares in the company.
In other recent news, Natera Inc (NASDAQ:). has expanded its patent infringement lawsuit against NeoGenomics (NASDAQ: ) over the RaDaR test, a test for molecular residual disease. The company reported record third-quarter revenue of $439.8 million, up 64% year-over-year, and performed 137,000 oncology tests, up 54% year-over-year. Amid these developments, TD Cowen, Baird and Jefferies maintained their favorable ratings on Natera’s stock and raised their price targets.
Natera also faced failure in a false advertising lawsuit Guardian of health (NASDAQ: ) but plans to ask the court to overturn the ruling. In addition, the company amended the contract with dr. Rabinowitz, executive chairman, to continue in her role under the terms of the contract.
These recent developments provide investors with an insight into the current status of Natera. The company continues to strengthen its position in the genetic testing industry, despite legal challenges and a competitive environment.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
